



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

JMJD7-IN-1

Cat. No.: HY-132198
CAS No.: 311316-96-8
Molecular Formula: C₁₆H₈Cl₂N₂O₄
Molecular Weight: 363.15
Target: Histone Demethylase
Pathway: Epigenetics
Storage: 4°C, protect from light
 * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 8.33 mg/mL (22.94 mM; ultrasonic and warming and heat to 60°C)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.7537 mL	13.7684 mL	27.5368 mL
	5 mM		0.5507 mL	2.7537 mL	5.5074 mL
	10 mM		0.2754 mL	1.3768 mL	2.7537 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

JMJD7-IN-1 is a potent JMJD7 inhibitor, with an IC₅₀ of 6.62 μM. JMJD7-IN-1 shows good inhibitory activity against cells expressing a high level of JMJD7^[1].

IC₅₀ & Target

IC₅₀: 6.62 μM (JMJD7)^[1]

In Vitro

JMJD7-IN-1 (0.1-1000 μM) dose-dependently inhibits the activity of JMJD7, with an IC₅₀ of 6.62 μM^[1].
 JMJD7-IN-1 efficiently binds to JMJD7, with an IC₅₀ of 3.80 μM^[1].
 JMJD7-IN-1 (72 h) inhibits the growth of T-47d, SK-BR-3, Jurkat and Hela cells, with IC₅₀s of 9.40 μM, 13.26 μM, 15.03 μM and 16.14 μM, respectively^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Zhang W, et, al. Discovery of JMJD7 inhibitors with the aid of virtual screening and bioactivity evaluation. Bioorg Med Chem Lett. 2021 May 25;45:128139.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA